The Herald
The SA National Blood Service is celebrating a life-saving milestone
The SA National Blood Service is celebrating a life-saving milestone

Two decades of advanced testing secure safer transfusions and greater diversity in donor pools

SANBS marks 21 years of pioneering blood safety technology

World-first national screening programme intercepted more than 5,000 viral infections across 18 million donations

SummaryOpen the quick read
  • South Africa marked 21 years since becoming the first country to roll out individual donor nucleic acid testing (ID-NAT) on a national scale in October 2005.
  • The screening method detects viral genetic material to dramatically shorten the diagnostic window period for HIV, Hepatitis B, and Hepatitis C.
  • Across approximately 18 million screened donations, the technology identified 5,166 window-period infections that conventional tests might have missed.
  • The transition enabled SANBS to abandon race-based donor risk profiling, supporting a rise in donations from black donors from 4% in 2005 to nearly 60% in 2026.
  • Total collections rose from 3.8 million between 2005 and 2010 to 5.8 million between 2021 and 2026, reinforcing South Africa's global standing in transfusion medicine.

Twenty-one years after becoming the first country to implement individual donor nucleic acid testing (ID-NAT) for individual blood donations at a national scale, the SA National Blood Service (SANBS) is reflecting on a significant chapter in the evolution of blood safety in SA.

The milestone was commemorated at a recent event held at The Maslow Hotel in Sandton, bringing together stakeholders to reflect on the scientific innovation, research and institutional commitment that have helped strengthen the safety of the country's blood supply.

Introduced in October 2005, ID-NAT marked a significant shift in how donated blood was screened for infectious diseases.

The technology detects the genetic material of HIV, Hepatitis B virus (HBV) and Hepatitis C virus (HCV), enabling infections to be identified earlier than conventional antibody-based screening methods alone and reducing the window period during which an infection may otherwise go undetected.

Over the past 21 years, the impact of this technology has been measurable.

SANBS data shows that approximately 18 million blood donations have been screened through NAT, identifying 5,166 NAT-yield cases involving HIV, HBV and HCV.

Of these cases, 3,995 (77%) were attributed to Hepatitis B, 1,093 (21%) to HIV and 78 (2%) to Hepatitis C.

These findings demonstrate the critical role of NAT in identifying infections that may otherwise escape earlier screening and in supporting SANBS's commitment to providing safe blood products to patients.

Commenting on the milestone, SANBS CEO Ravi Reddy, said: “Twenty-one years ago, the introduction of individual donor nucleic acid testing represented a defining moment in our commitment to safer blood.

"It was not simply the adoption of new technology; it was a fundamental advancement in how we manage risk, protect patients and build confidence in the national blood supply.

"The impact of this investment is reflected in millions of donations screened, infections identified and, most importantly, the continued strengthening of blood safety in SA.

"As we reflect on this achievement, we remain committed to advancing science, research and innovation to ensure that patients receive the safest possible blood products.”

Beyond improving the detection of infectious diseases, the introduction of ID-NAT also contributed to a broader transformation in SA's blood donation model.

Before its implementation, SANBS faced significant challenges in managing the risk of transfusion-transmitted infections during the HIV pandemic.

Following engagements with the national department of health in 2004, the organisation received approval to implement ID-NAT, moving away from race-based donor risk management towards individual-donation testing.

This transition supported a more inclusive approach to blood donation.

SANBS data indicates that the proportion of donations from black donors increased from approximately 4% in 2005 to almost 60% in 2026.

The growth in collections further reflects this transformation.

Total blood collections increased from 3.8 million during 2005–2010 to 5.8 million during 2021–2026, demonstrating the expansion of the donor base and the organisation's capacity to support the country's blood supply.

The milestone also highlights SANBS's contribution to scientific research and the advancement of transfusion medicine.

Over the years, findings from its NAT programme have informed peer-reviewed research examining window-period infections, donor behaviour, HIV testing and the impact of antiretroviral treatment on blood screening.

Through its participation in the Recipient Epidemiology and Donor Evaluation Study (REDS-III), SANBS also contributed to research supported by a US$7 million (about R118.3m) grant, strengthening scientific understanding of HIV among SA blood donors and the effectiveness of blood screening technologies.

The organisation's commitment to quality and innovation has also received international recognition.

In 2011, the World Health Organisation commended SANBS as one of the top five blood services globally, recognising its national model, blood supply, blood safety protocols and ISO 15189 accreditation.